|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 索凡替尼>> 市场分析报告 |
索凡替尼市场分析报告 |
|
Thyroid cancer - Pipeline Insight, 2021 ... DEBIO 1124 Gavreto Encorafenib Binimetinib Surufatinib CDX-3379 VB-111 BVA 701 ... Biliary Tract Cancer - Pipeline Insight, 2021 ... Ramucirumab Nanoliposomal Irinotecan TH-302 DKN-01 Surufatinib TQB2450 Trastuzumab deruxtecan Envafolimab SC-43 INCB001158 ... Macrophage colony stimulating factor receptor antagonists - Pipeline Insight, 2022 ... NMS 03592088 Q 702 Emactuzumab Elzovantinib Surufatinib EI 003 EI 1071 BCI 1415 IMC ... Vascular endothelial growth factor receptor-2 antagonists - Pipeline Insight, 2022 ... LYN 00101 TransCon VEGF-TKI Surufatinib Axitinib Axitinib implant Sorafenib nanoparticle ... Vascular endothelial growth factor receptor 3 antagonists - Pipeline Insight, 2022 ... 292 AZD-2171 CLS 1002 Surufatinib Catequentinib Sitravatinib Axitinib AIV 007 ... Thyroid Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034 The 7 major thyroid cancer markets reached a value of US$ 303.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,624.3 Million by 2034, exhibiting a growth rate (CAGR) of 16.49% during 2024-2034. The thyroid cancer market has ... Hutchmed China Ltd - Company Profile and SWOT Analysis ... endothelial growth factor receptor (VEGFR) 1/2/3; surufatinib, a novel, oral angio-immuno kinase ... |